HUBEI PROVINCE, China, May 13 /Xinhua-PRNewswire-FirstCall/ -- Benda
Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based
pharmaceutical company producing both Gendicine(R), a commercialized gene
therapy medicine for the treatment of cancer, and traditional Chinese and
conventional medicines, today announced that its subsidiary, Jiangling
Benda Pharmaceutical Co., Ltd. ("Jiangling Benda"), has received the Good
Manufacturing Practice ("GMP") certificate by the Chinese State Food and
Drug Administration ("SFDA") authorizing the production of Ribavrin at its
Jiangling Plant.
"We are very excited that our Jiangling plant has successfully obtained
the GMP certificate. This certificate represents the endorsement of our
quality control system and production facilities by the SFDA, and is a
major step to launch and market our Ribavrin in the domestic market,"
stated Charles Wan, Chief Executive Officer of Benda Pharmaceutical.
Jiangling Benda plans to produce four types of Active Pharmaceutical
Ingredients (APIs), including Ribavrin, Asarin, Levofloxacin Mesylate and
Ribose. The production of the APIs, with the exception of Ribose, requires
GMP certification. The Jiangling plant was closed for renovation in July
2004 to comply with GMP standards and was reopened in August 2007 for the
production of Ribose. It currently has all of the production equipment in
place, and the new facilities have been installed and tested for Ribavrin
and Ribose.
Additional information regarding this certificate, issued on April 9,
2008, can be found on the SFDA website ( http://www.sfda.gov.cn ).
About Jiangling Benda
Jiangling Benda develops, manufactures and sells Active Pharmaceutical
Ingredients ("APIs"), which are one of the two components of any capsules,
tablets and fluids that are pharmaceutically active. An API is the
substance in a drug that produces the desired medicinal effect. The
"excipient" is the inert material that holds the API (such as gelatin or
water). About 3.7 per cent of the APIs that Jiangling Benda produced in
2004 were used to produce some of the company's finished medicines. The
remainder was sold in the market to unrelated parties. Jiangling Benda did
not sell to related Benda companies in 2006 or 2007.
About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a
China-based pharmaceutical company, produces traditional Chinese and
conventional medicines, as well as Gendicine(R), a commercialized gene
therapy medicine for the treatment of cancer.
Safe Harbor Statement
The information contained herein includes forward-looking statements.
These statements relate to future events or to our future financial
performance, and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity, performance,
or achievements to be materially different from any future results, levels
of activity, performance or achievements expressed or implied by these
forward- looking statements. You should not place undue reliance on
forward-looking statements since they involve known and unknown risks,
uncertainties and other factors which are, in some cases, beyond our
control and which could, and likely will, materially affect actual results,
levels of activity, performance or achievements. Any forward-looking
statement reflects our current views with respect to future events and is
subject to these and other risks, uncertainties and assumptions relating to
our operations, results of operations, growth strategy and liquidity. We
assume no obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results could
differ materially from those anticipated in these forward-looking
statements, even if new information becomes available in the future. The
safe harbor for forward-looking statements contained in the Securities
Litigation Reform Act of 1995 protects companies from liability for their
forward-looking statements if they comply with the requirements of the Act.
SOURCE Benda Pharmaceutical, Inc.
 back to top
Related links:
http://www.bendapharma.com
CONTACT:
Ashley Ammon MacFarlane and Christine Duan,
Investor Relations, at +1-203-682-8200, both of Integrated
Corporate Relations, Inc. for Benda Pharmaceutical, Inc.
|
